Roche's new breast cancer treatment Kadcyla has been rejected by NICE in draft guidance, with the cost effectiveness watchdog criticising the high price set by the company. NICE says Kadcyla costs ...
NICE first rejected Kadcyla back in 2014, saying its cost of around £91,000 per patient at full price was too high, and that a small discount was not enough for it to be considered cost effective.
The cost of Kadcyla can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Kadcyla. As with all ...